GSK and Pfizer Compete in RSV Vaccine Market with New Approvals and Data
Pfizer's Abrysvo has received FDA approval for use in adults aged 18 to 59 who are at higher risk of developing lower respiratory tract disease (LRTD) caused by RSV, marking it as the first RSV vaccine approved for this younger demographic[2][3][5]. This approval extends from earlier clearances for individuals over 60 and pregnant women, allowing Pfizer to enhance its market presence against competitors like GSK's Arexvy[1][3]. The decision is supported by the Phase 3 MONeT trial, which demonstrated strong immune responses among high-risk groups, paving the way for further outreach in the RSV vaccine market[4][5].
References
- GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
- With expanded FDA nod for RSV shot Abrysvo, Pfizer gains edge on GSK's Arexvy. But will it amount to much?
- Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
- Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
- U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
Explore Further
How might GSK and Pfizer's strategies shift based on future CDC recommendations for RSV vaccination?
What are the potential implications of Pfizer's FDA approval for Abrysvo on GSK's Arexvy sales and market strategy?
In what ways could the upcoming clinical data presentations impact the competition between GSK and Pfizer in the RSV vaccine market?
How significant is the impact of CDC's narrowed RSV vaccination recommendations on the market uptake for Pfizer and GSK?
What are the main challenges faced by GSK and Pfizer in expanding the use of their RSV vaccines to younger populations?